JP2014500885A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014500885A5 JP2014500885A5 JP2013541447A JP2013541447A JP2014500885A5 JP 2014500885 A5 JP2014500885 A5 JP 2014500885A5 JP 2013541447 A JP2013541447 A JP 2013541447A JP 2013541447 A JP2013541447 A JP 2013541447A JP 2014500885 A5 JP2014500885 A5 JP 2014500885A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- compound according
- disorders
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 29
- 150000003839 salts Chemical class 0.000 claims 14
- 239000011780 sodium chloride Substances 0.000 claims 14
- 206010057668 Cognitive disease Diseases 0.000 claims 4
- 206010003736 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 208000008238 Muscle Spasticity Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 206010001897 Alzheimer's disease Diseases 0.000 claims 1
- 206010002026 Amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 206010002855 Anxiety Diseases 0.000 claims 1
- 206010057666 Anxiety disease Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 206010004938 Bipolar disease Diseases 0.000 claims 1
- 208000006752 Brain Edema Diseases 0.000 claims 1
- 206010048962 Brain oedema Diseases 0.000 claims 1
- 206010007515 Cardiac arrest Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 208000008208 Craniocerebral Trauma Diseases 0.000 claims 1
- 206010011878 Deafness Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000001187 Dyskinesias Diseases 0.000 claims 1
- 206010015037 Epilepsy Diseases 0.000 claims 1
- 208000010496 Heart Arrest Diseases 0.000 claims 1
- 201000001971 Huntington's disease Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 208000002780 Macular Degeneration Diseases 0.000 claims 1
- 206010027599 Migraine Diseases 0.000 claims 1
- 208000008085 Migraine Disorders Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000009025 Nervous System Disease Diseases 0.000 claims 1
- 206010029305 Neurological disorder Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 206010061536 Parkinson's disease Diseases 0.000 claims 1
- 208000008425 Protein Deficiency Diseases 0.000 claims 1
- 206010037175 Psychiatric disease Diseases 0.000 claims 1
- 206010061920 Psychotic disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 206010038932 Retinopathy Diseases 0.000 claims 1
- 206010039911 Seizure Diseases 0.000 claims 1
- 206010040984 Sleep disease Diseases 0.000 claims 1
- 208000008513 Spinal Cord Injury Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000009205 Tinnitus Diseases 0.000 claims 1
- 206010044565 Tremor Diseases 0.000 claims 1
- 206010044652 Trigeminal neuralgia Diseases 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 230000001154 acute Effects 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 201000006287 attention deficit hyperactivity disease Diseases 0.000 claims 1
- 201000002055 autistic disease Diseases 0.000 claims 1
- 201000006474 brain ischemia Diseases 0.000 claims 1
- 230000019771 cognition Effects 0.000 claims 1
- 201000009929 conduct disease Diseases 0.000 claims 1
- 231100000895 deafness Toxicity 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 231100000040 eye damage Toxicity 0.000 claims 1
- 230000002218 hypoglycaemic Effects 0.000 claims 1
- 230000001146 hypoxic Effects 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 200000000018 inflammatory disease Diseases 0.000 claims 1
- 201000004044 liver cirrhosis Diseases 0.000 claims 1
- 201000008895 mood disease Diseases 0.000 claims 1
- 230000001537 neural Effects 0.000 claims 1
- 231100000886 tinnitus Toxicity 0.000 claims 1
Claims (15)
- 式Ｉ、ＩＡ、ＩＢ、ＩＩ、ＩＩＡ、ＩＩＢ、ＩＩＩ、ＩＩＩＡ、もしくはＩＩＩＢの化合物
- 化合物が、
- 化合物が式ＩＡの化合物である、請求項２に記載の化合物または薬学的に許容できるその塩。
- 化合物のｅｅが少なくとも９５％である、請求項３に記載の化合物または薬学的に許容できるその塩。
- 化合物のｅｅが少なくとも９９％である、請求項３に記載の化合物または薬学的に許容できるその塩。
- 化合物が、
- 化合物が式ＩＩＡの化合物である、請求項６に記載の化合物または薬学的に許容できるその塩。
- 化合物のｅｅが少なくとも９５％である、請求項７に記載の化合物または薬学的に許容できるその塩。
- 化合物のｅｅが少なくとも９９％である、請求項７に記載の化合物または薬学的に許容できるその塩。
- 化合物が、
- 化合物が式ＩＩＩＡの化合物である、請求項１０に記載の化合物または薬学的に許容できるその塩。
- 化合物のｅｅが少なくとも９５％である、請求項１１に記載の化合物または薬学的に許容できるその塩。
- 化合物のｅｅが少なくとも９９％である、請求項１１に記載の化合物または薬学的に許容できるその塩。
- 請求項１から１３のいずれか一項に記載の化合物または薬学的に許容できるその塩と、薬学的に許容できる担体とを含む医薬組成物。
- 急性神経障害および精神障害、卒中、脳虚血、脊髄外傷、認知機能障害、頭部外傷、周産期低酸素症、心停止、低血糖性神経損傷、認知症、アルツハイマー病、ハンチントン舞踏病、筋萎縮性側索硬化症、眼損傷、網膜症、認知障害、特発性および薬物誘発性パーキンソン病、筋痙縮および振戦を含めた筋肉の痙縮と関連する障害、てんかん、けいれん、片頭痛、尿失禁、物質耐性、物質離脱、精神病、統合失調症、統合失調症と関連する陰性症状、自閉症、双極性障害、うつ病、うつ病と関連する認知機能障害、がん治療と関連する認知機能障害、不安、気分障害、炎症性障害、敗血症、硬変、免疫応答回避と関連するがんおよび／または腫瘍、三叉神経痛、失聴、耳鳴、眼の黄斑変性、嘔吐、脳浮腫、疼痛、遅発性ジスキネジア、睡眠障害、注意欠陥／多動性障害、注意欠陥障害、注意および／または認知の欠陥を症状として含む障害、ならびに行為障害からなる群から選択される状態を治療または予防するための、請求項１４に記載の医薬組成物。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41879110P | 2010-12-01 | 2010-12-01 | |
| US61/418,791 | 2010-12-01 | ||
| US41923210P | 2010-12-02 | 2010-12-02 | |
| US61/419,232 | 2010-12-02 | ||
| PCT/IB2011/055190 WO2012073146A1 (en) | 2010-12-01 | 2011-11-18 | Kat ii inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014500885A JP2014500885A (ja) | 2014-01-16 |
| JP2014500885A5 true JP2014500885A5 (ja) | 2014-12-18 |
| JP5868994B2 JP5868994B2 (ja) | 2016-02-24 |
Family
ID=45315857
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013541447A Expired - Fee Related JP5868994B2 (ja) | 2010-12-01 | 2011-11-18 | Ｋａｔｉｉ阻害剤 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8487104B2 (ja) |
| EP (1) | EP2646417A1 (ja) |
| JP (1) | JP5868994B2 (ja) |
| KR (1) | KR101522803B1 (ja) |
| CN (1) | CN103228631B (ja) |
| AR (1) | AR084051A1 (ja) |
| AU (1) | AU2011336217B2 (ja) |
| CA (1) | CA2819106C (ja) |
| HK (1) | HK1187611A1 (ja) |
| IL (1) | IL226668A (ja) |
| MX (1) | MX2013005915A (ja) |
| SG (1) | SG190246A1 (ja) |
| WO (1) | WO2012073146A1 (ja) |
| ZA (1) | ZA201303412B (ja) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2014014808A (es) * | 2012-06-15 | 2015-02-12 | Pfizer | Compuestos triciclicos como inhibidores de kat ii. |
| US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| CA2946702C (en) * | 2014-04-23 | 2022-06-28 | Mitsubishi Tanabe Pharma Corporation | Bicyclic or tricyclic heterocyclic compound |
| WO2016191288A1 (en) | 2015-05-22 | 2016-12-01 | Agenebio, Inc. | Extended release pharmaceutical compositions of levetiracetam |
| EP3372601B1 (en) | 2015-10-22 | 2022-09-21 | Mitsubishi Tanabe Pharma Corporation | Novel bicyclic heterocyclic compound |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4208304A1 (de) * | 1992-03-16 | 1993-09-23 | Merck Patent Gmbh | 2-oxochinolinderivate |
| US5594006A (en) * | 1993-03-18 | 1997-01-14 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives as matrix metalloproteinases inhibitors |
| JPH0881443A (ja) * | 1994-09-12 | 1996-03-26 | Otsuka Pharmaceut Co Ltd | 細胞外マトリックス金属プロテアーゼ阻害剤 |
| WO2005007111A2 (en) * | 2003-07-11 | 2005-01-27 | Bristol-Myers Squibb Company | Tetrahydroquinoline derivatives as cannabinoid receptor modulators |
| WO2009064836A2 (en) * | 2007-11-15 | 2009-05-22 | University Of Maryland, Baltimore | Kynurenine-aminotransferase inhibitors |
| KR101390023B1 (ko) * | 2009-06-18 | 2014-04-29 | 화이자 인코포레이티드 | 키누레닌 아미노트랜스퍼라제 ｉｉ 억제제로서 이환식 및 삼환식 화합물 |
| EP2646443B1 (en) | 2010-12-01 | 2014-09-24 | Pfizer Inc | Kat ii inhibitors |
-
2011
- 2011-11-18 WO PCT/IB2011/055190 patent/WO2012073146A1/en active Application Filing
- 2011-11-18 CA CA2819106A patent/CA2819106C/en not_active Expired - Fee Related
- 2011-11-18 KR KR1020137016959A patent/KR101522803B1/ko not_active IP Right Cessation
- 2011-11-18 CN CN201180057792.0A patent/CN103228631B/zh not_active Expired - Fee Related
- 2011-11-18 MX MX2013005915A patent/MX2013005915A/es not_active Application Discontinuation
- 2011-11-18 EP EP11794240.9A patent/EP2646417A1/en not_active Withdrawn
- 2011-11-18 AU AU2011336217A patent/AU2011336217B2/en not_active Ceased
- 2011-11-18 SG SG2013036314A patent/SG190246A1/en unknown
- 2011-11-18 JP JP2013541447A patent/JP5868994B2/ja not_active Expired - Fee Related
- 2011-11-30 AR ARP110104458A patent/AR084051A1/es not_active Application Discontinuation
- 2011-11-30 US US13/307,140 patent/US8487104B2/en not_active Expired - Fee Related
-
2013
- 2013-05-10 ZA ZA2013/03412A patent/ZA201303412B/en unknown
- 2013-05-30 IL IL226668A patent/IL226668A/en not_active IP Right Cessation
-
2014
- 2014-01-17 HK HK14100556.0A patent/HK1187611A1/xx not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013544277A5 (ja) | ||
| JP2009509920A5 (ja) | ||
| JP2014500885A5 (ja) | ||
| RU2009147708A (ru) | Производные оксадиазола и их применение в качестве потенцирующих средств метаботропных глутаматных рецепторов-842 | |
| TN2018000299A1 (en) | Heterocyclic compound. | |
| PH12015502502A1 (en) | Heteroaromatic compounds and their use as dopamine d1 ligands | |
| DOP2018000204A (es) | Moduladores alostéricos de receptores de acetilcolina nicotínicos | |
| ECSP19048477A (es) | Inhibidores biciclo[1.1.1]pentano de la cinasa de cremallera de leucina dual (dlk) para el tratamiento de enfermedades | |
| JP2012530129A5 (ja) | ||
| EA201390971A1 (ru) | ИМИДАЗО[5,1-f][1,2,4]ТРИАЗИНЫ ДЛЯ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ РАССТРОЙСТВ | |
| GEP201706608B (en) | 1 - arylcarbonyl - 4 - oxy – piperidine compounds useful for the treatment of neurodegenerative diseases | |
| JP2015511958A5 (ja) | ||
| PH12014502670A1 (en) | Prodrug of fluorine - containing amino acid | |
| PH12018502211A1 (en) | Prodrug of amino acid derivative | |
| MX2016008842A (es) | Derivados de n-fenil-lactama capaces de estimular la neurogenesis y su uso en el tratamiento de trastornos neurologicos. | |
| JP2013519728A5 (ja) | ||
| PH12016501863A1 (en) | Heteroaromatic compounds and their use as dopamine d1 ligands | |
| CY1120148T1 (el) | Ενωσεις ουριας και η χρηση τους ως ενζυμικοι αναστολεις | |
| AR112683A1 (es) | Forma cristalina de base libre de levodopa, su sal de adición y composición farmaceutica que la comprende | |
| PH12016501993A1 (en) | Heteroaromatic compounds and their use as dopamine d1 ligands | |
| IN2014DN09826A (ja) | ||
| RU2016132574A (ru) | Органические соединения | |
| MX346794B (es) | Nuevas sales cristalinas de adicion de acido de derivado triciclico o hidruro del mismo y metodo de produccion de las mismas. | |
| PH12016500605A1 (en) | Pyrido[4,3-b]pyrazine-2-carboxamides as neurogenic agents for the treatment of neurodegenerative disorders | |
| JP2017502069A5 (ja) |